AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 262 min read$GSK

GSK gets positive results in drug trials for rectal and ovarian cancer

GSK reported positive trial results for Jemperli in rectal cancer and Mo-Rez in ovarian cancer. 76% of rectal cancer patients showed complete response to Jemperli, avoiding surgery. Mo-Rez showed durable responses in ovarian cancer. GSK shares rose 1.1% to 1,914.50 pence.

Original reporting
marketscreener.com
Published Oct 26, 2026, 9:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GSK
Bullish
high confidence
Mentioned
$GSK
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The data could lift GSK's share price ahead of its Q3 earnings and may influence analyst outlooks on its oncology franchise.

02

Market read

First‑report positive Phase II data for two oncology candidates, likely to generate short‑term buying interest.

03

What to watch

Potential safety concerns, reimbursement challenges, and competition from other checkpoint inhibitors could temper upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

GSK announced the results of two separate oncology trials, highlighting efficacy in rectal and ovarian cancers.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK reported positive Phase II trial results for Jemperli in rectal cancer and Mo-Rez in platinum‑resistant ovarian cancer.

Expected impact

upward pressure as market prices in the encouraging efficacy results.

Evidence & confidence

Phase II data showing high response rates and durable outcomes typically lift biotech stocks, especially when combined with an upcoming earnings release.

Market effects

Sector

Strengthens the oncology pipeline outlook for large‑cap pharma and may raise expectations for other checkpoint‑inhibitor developers.

Regional

European pharma stocks could see modest gains as the data underscores the region's R&D capabilities.

Global

Adds to the broader narrative of advancing immunotherapy treatments worldwide.

Counterpoint

What could challenge this read

Investors may question the commercial viability until Phase III data and regulatory approval are secured.

Key entities

  • company
    GSK PLC

    British multinational pharmaceutical company.

  • drug
    Jemperli (dostarlimab)

    PD‑1 inhibitor being tested for rectal cancer.

  • drug
    Mo‑Rez (mocertatug rezetecan)

    Investigational therapy for platinum‑resistant ovarian cancer.

Read at source← All news

StoryGSK reports 76% complete response for Jemperli in rectal cancer and 62% response for Mo‑Rez in ovarian cancer

Also covered by

1 outlet

Related articles

OCT 26
$GSKMed

GSK plc Announces Updated Data From Global Phase I BEHOLD-1 Trial For Mo-Rez In Platinum-Resistant Ovarian Cancer

GSK plc reported updated phase I trial data for Mo-Rez, showing a 62% objective response rate and 12.2-month median duration of response in platinum-resistant ovarian cancer. The data will be presented at ESMO 2026, with phase III trials ongoing. Safety results were consistent with prior data, with 71% of patients experiencing grade 3 adverse events.

marketscreener.com2 min
OCT 26
$GSKMed

GSK plc Announces Positive Interim Results From Phase II AZUR-1 Trial Evaluating Jemperli Monotherapy In Adults With Stage II And III MSI-H/dMMR Locally Advanced Rectal Cancer

GSK plc reported positive interim results from its phase II AZUR-1 trial of Jemperli (dostarlimab) monotherapy for stage II and III MSI-H/dMMR locally advanced rectal cancer. 76% of evaluable patients achieved a complete response, with 68% sustaining it for at least 12 months. The trial met its primary objective, and no disease recurrences were reported. Adverse reactions were consistent with Jemperli's known profile.

marketscreener.com2 min
OCT 26
$GSKHigh

Hansoh and GSK drug extends survival in bone cancer study

Hansoh Pharmaceutical (HK:3692) and GSK (LON:GSK) reported that their experimental osteosarcoma drug, ris-rez, extended disease-free survival to 5.5 months vs. 1.4 months with chemotherapy in a late-stage trial. The drug reduced progression/death risk by 67%. GSK licensed ris-rez and is accelerating its development in oncology.

investing.com2 min
OCT 26
$GSKMed

GSK Presents Two Cancer Datasets at ESMO

GSK presented cancer trial data at ESMO Congress. Mo-Rez showed 62% response rate in ovarian cancer, with 71% adverse events. Jemperli had 76% complete response in rectal cancer, with 47% sustained at 12 months. GSK shares closed Friday at 1894p, down 1.04%.

asktraders.com2 min
OCT 26
$GSKHighAI 9/10

Key facts: GSK plc Sponsored ADR Q3 Oct28; BEHOLD; Mo-Rez ORR 62%

GSK (Sponsored ADR) is set to report Q3 2026 results on Oct 28, with expected revenue of ~$11.6B (up 0.7% YoY) and EPS of $1.33. The mean 12-month price target is $58.43. Additionally, GSK's BEHOLD program and Mo-Rez phase I trial in ovarian cancer showed an ORR of 62% and a median PFS of 11.1 months, with data to be presented at ESMO Congress 2026.

tradingview.com1 min
OCT 26
$GSKMed

GSK rectal cancer drug clears tumours in 76% of patients without surgery or chemotherapy

GSK's immunotherapy Jemperli (dostarlimab) showed a 76% complete response rate in rectal cancer patients without surgery or chemotherapy, per interim phase II trial results. 76% of 144 patients had no cancer evidence after treatment, with 68% sustaining response for at least 12 months. No recurrences reported after over two years. US approval granted; data presented at ESMO congress. Serious side effects occurred in 20% of patients.

themarketreporter.co.uk2 min